Truist Securities Reiterates Buy Rating on Beta Bionics, Inc. (BBNX)

Market Context

Beta Bionics, Inc. operates in the Healthcare sector. The stock currently trades at $16.95 with a market capitalization of $1.3B. The stock has gained 25.0% over the past 52 weeks.

Analyst coverage from Truist Securities provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Beta Bionics, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Beta Bionics, Inc.

Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 13, 2026	Truist Securities	Buy	N/A
May 27, 2026	Goldman Sachs	Buy	N/A
May 18, 2026	B of A Securities	Neutral	N/A
Apr 22, 2026	Leerink Partners	Outperform	N/A
Apr 22, 2026	Stifel	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View BBNX Stock Page